EGFR and lung adenocarcinoma: In conclusion, for patients with advanced lung adenocarcinoma, the use of first-line EGFR-TKIs in patients who harbored the EGFR 19 del might be associated with higher ORR and longer PFS compared with patients who carried the L858R mutation.